CTOs on the Move

Plexium

www.plexium.com

 
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.plexium.com
  • 11494 Sorrento Valley Road
    San Diego, CA USA 92121
  • Phone: 858.263.7491

Executives

Name Title Contact Details
Daniel Sipes
Senior Vice President and Head of Technology Profile

Funding

Plexium raised $28M on 10/17/2019
Plexium raised $35M on 01/19/2021

Similar Companies

Nutra-C

Nutra-C is a Laurel, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.

Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.

Virtual Radiologic Corporation

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.

Ocugen

Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.